Mirum Pharmaceuticals Inc (STU:08D)
€ 38.8 0.6 (1.57%) Market Cap: 1.92 Bil Enterprise Value: 1.95 Bil PE Ratio: 0 PB Ratio: 8.72 GF Score: 52/100

Mirum Pharmaceuticals Inc at UBS BioPharma Conference Transcript

Nov 08, 2023 / 07:00PM GMT
Release Date Price: €27.6 (+2.22%)
Eliana Rachel Merle
UBS Investment Bank, Research Division - Analyst

All right. I think we're going to get started. We're running a minute or 2 behind. I'm Ellie Merle, one of the biotech analysts here at UBS. Very happy to have Mirum Pharma here with us at the UBS Biopharma Conference in Miami.

Joining us from Mirum is Eric Bjerkholt, Chief Financial Officer; and Andrew McKibben, VP, Investor Relations and Finance. Guys, thanks so much for joining us. Maybe just to kick it off, you guys have a pretty wide portfolio in most commercial and clinical programs. Can you give us an overview of your pipeline and what you see as the key milestones over the next year?

Eric H. Bjerkholt
Mirum Pharmaceuticals, Inc. - CFO

Absolutely. And Ellie, thanks for having us. It's really fun to be here. And before I start answering the questions, let me say, both Andrew and I will be making forward-looking statements. So please refer to our SEC filings.

So we are building a leading company in rare diseases. Currently, we have 3 approved products for liver

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot